FilingReader Intelligence

Dian Diagnostics reports revenue dip, plans cash dividend

April 23, 2025 at 05:28 AM UTCBy FilingReader AI

Dian Diagnostics Group (SZSE:300244) announced its 2024 annual results, detailing a 9.04% year-over-year revenue decrease to CNY 12.196 billion. The company posted a net loss attributable to shareholders of CNY 357.278 million for the year. Despite these challenges, Dian Diagnostics' board has proposed a cash dividend of CNY 2.50 per 10 shares, totaling CNY 152.77 million. This proposal is slated for shareholder approval on April 22, 2025.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SZSE:300244Shenzhen Stock Exchange
Pharmaceuticals

News Alerts

Get instant email alerts when Dian Diagnostics Group publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →